Clinical Trial Update: StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating StemRegenin-1-expanded versus unexpanded umbilical cord blood for high-risk hematologic malignancies has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• StemRegenin-1 (StemRegenin-1)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Status: WITHDRAWN